Efficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia: A Phase 3, Randomized, Double-Blind Placebo-Controlled Study

Efficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia: A Phase 3, Randomized, Double-Blind Placebo-Controlled Study

Abstract Introduction Polymorphonuclear cell influx into the interstitial and bronchoalveolar spaces is a cardinal feature of severe coronavirus disease 2019 (COVID-19), principally mediated by interleukin-8 (IL-8). We sought to determine whether reparixin, a novel IL-8 pathway inhibitor, could redu...

Full description

Bibliographic Details
Main Authors: Lorenzo Piemonti, Giovanni Landoni, Antonio Voza, Massimo Puoti, Ivan Gentile, Nicola Coppola, Stefano Nava, Alessia Mattei, Franco Marinangeli, Giulia Marchetti, Paolo Bonfanti, Claudio Maria Mastroianni, Matteo Bassetti, Ernesto Crisafulli, Paolo Antonio Grossi, Alberto Zangrillo, Antonio Desai, Marco Merli, Maria Foggia, Marco Carpano, Lorenzo Schiavoni, Antonella D’Arminio Monforte, Luca Bisi, Gianluca Russo, Fabiana Busti, Cristina Rovelli, Elisabetta Perrotta, Giovanni Goisis, Elizabeth M. Gavioli, Sophie Toya, Maria De Pizzol, Flavio Mantelli, Marcello Allegretti, Enrico Maria Minnella
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-10-01
Series:Infectious Diseases and Therapy
Subjects:
COVID-19
Interleukin-8 (IL-8)
Reparixin
SARS-CoV-2
Online Access:https://doi.org/10.1007/s40121-023-00871-5

Internet

https://doi.org/10.1007/s40121-023-00871-5

Similar Items